Octapharma recently announced new data on the benefits of their recombinant factor VIII therapy Nuwiq® in patients with hemophilia A. Nuwiq® is indicated for on-demand treatment and control of bleeding episodes and routine prophylaxis to reduce the frequency of bleeding episodes and perioperative management of bleeding. The data, which included previously untreated patients (PUPs), was presented in a scientific symposium at the just-completed XXVII Congress of the International Society on Thrombosis and Haemostasis (ISTH). The Congress was held July 6-10, 2019 in Melbourne, Australia.
The symposium, “Conveniently Protecting What Matters: Nuwiq® (Simoctocog Alfa) in PUPs and Personalized Prophylaxis,” included final data from the NuProtect Study in PUPs. It focused on the use of pharmacokinetic (PK) information to personalize prophylactic therapy with Nuwiq®. PK information is important as it denotes the measurement of concentration and duration of a drug’s effect in the body. PK tests, a key component of personalized treatment, can be used to target factor levels that will help achieve a desired therapeutic response.
According to a recent press release, the individualized dosing approach enabled over half (57%) of patients to reduce dosing with Nuwiq® to twice-weekly or less, while also providing effective protection from bleeds. The results showed that 83% of enrolled patients experienced zero spontaneous bleeds during the six month period of personalized prophylaxis with the therapy. In addition, no FVIII inhibitors, or serious adverse events were reported.
“The data presented at the symposium build on a broad clinical experience with Nuwiq®, said Olaf Walter, Board Member at Octapharma. “The ISTH congress is a key platform for exchanging information in the international hemophilia field and we are proud to present these new and robust data in PUPs, which we believe will help to improve hemophilia A treatment”.
Source: Businesswire press release dated July 8, 2019